🇺🇸 FDA
Patent

US 10138272

Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

granted A61KA61K2039/505A61K47/65

Quick answer

US patent 10138272 (Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
43
CPC classes
A61K, A61K2039/505, A61K47/65, A61K47/6835, A61K47/6889